- Current report filing (8-K)
03 6월 2011 - 10:09PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2011
TIENS BIOTECH GROUP (USA), INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32477
|
|
75-2926439
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
of incorporation)
|
|
|
|
Identification Number)
|
No. 6, Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China 301700
(Address of principal executive offices)
Registrant's telephone number, including area code:
(86) 22-8213-7658
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 27, 2011, Tiens Biotech Group (USA), Inc. (the “Company”) held its annual meeting of stockholders (“Annual Meeting”) to vote on the following matters:
1. Election of Directors
All of the following five nominees were elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.
|
|
|
|
|
|
|
|
|
Jinyuan Li
|
|
67,960,358
|
|
2,950
|
|
283,744
|
|
0
|
Yupeng Yan
|
|
67,963,112
|
|
196
|
|
283,744
|
|
0
|
Baolan Li
|
|
67,960,358
|
|
2,950
|
|
283,744
|
|
0
|
Socorro Quintero
|
|
67,963,262
|
|
46
|
|
283,744
|
|
0
|
Gilbert Raker
|
|
67,963,262
|
|
46
|
|
283,744
|
|
0
|
2. Ratification of the Company’s Independent Auditors
Stockholders ratified the appointment of Crowe Horwath LLP (“Crowe”) as independent auditors to audit the financial statements of the Company for the 2011 fiscal year, in accordance with the voting results listed below.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TIENS BIOTECH GROUP (USA), INC.
|
|
|
|
Date: June 3, 2011
|
By:
|
/s/ Jinyuan Li
|
|
|
Name: Jinyuan Li
|
|
|
Title: Chief Executive Officer
|
Tiens Biotech GR Usa (AMEX:TBV)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Tiens Biotech GR Usa (AMEX:TBV)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024